May 12th 2024
Training at a major academic center offers firsthand exposure to groundbreaking 177Lu-PSMA-617 treatment for advanced prostate cancer.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Appeal of Physician-Dispensed Abiraterone and Enzalutamide for mCRPC Grows Stronger
November 11th 2015With novel treatments such as abiraterone acetate (Zytiga) and enzalutamide (Xtandi) emerging and financial challenges of diminished reimbursement faced by urology practices mounting, urology groups are beginning to offer in-office dispensing to their metastatic castration-resistant prostate cancer (mCRPC) patients.
Read More
Long-Term Study Reports RT Plus Anti-Androgen Improves Prostate Cancer Survival
October 23rd 2015Patients who had prostate cancer recurrence after radical prostatectomy lived significantly longer with the addition of hormonal therapy to salvage radiotherapy, long-term follow-up from a randomized trial showed.
Read More
Brief RT for Early Prostate Cancer Gets High Marks in Preliminary Trial
October 22nd 2015Ultra-hypofractionated radiation therapy for low-risk prostate cancer led to significantly lower rates of bowel and urinary dysfunction compared with patients treated with conventional radiotherapy regimens.
Read More
Prostate Cancer Study Shows Hypofractionation Comparable to Standard Radiation in Low-risk Patients
October 21st 2015Hypofractionated radiotherapy can achieve similar cure rates with similar side effects compared with conventional radiotherapy for men with low-risk, early prostate cancer, according to a recent study.
Read More
Prostate Surgery To Be Done With High-Intensity Ultrasound Device
October 14th 2015The FDA has announced clearance for a minimally invasive high-intensity focused ultrasound (HIFU) prostate tissue ablation device called Sonablate 450, making HIFU available in the United States for the first time.
Read More
Key to New Treatments: Discovering What Turns a Hedgehog Off
October 14th 2015Researchers note that chronic Hedgehog (Hh) pathway stimulation has been shown in prostate, lung, and ovarian cancers, and that zinc levels decrease early in prostate cancer continuing to castration-resistant disease. Researchers are exploring whether or not zinc may suppress the autocatalysis in the Hh precursor and inhibit production of biologically active Hh ligand.
Read More
Tasquinimod Discontinuation in mCRPC Highlights Need for Better Clinical Trial Design
October 2nd 2015Tasquinimod demonstrated promise in phase II trials but failed to improve overall survival in a phase III trial in treatment-naive metastatic castration-resistant prostate cancer; some experts believe this failure highlights the need for more intelligent clinical trial designs in prostate cancer.
Read More
Massive Trial in Prostate Cancer Supports Accelerated Hypofractionated Radiotherapy
September 30th 2015Accelerated hypofractionated radiotherapy using a schedule of 60 Gy in 20 fractions of 3 Gy delivered in 4 weeks was found to be comparable to the conventional schedule of 74 Gy/37 of 2 GY delivered in 7.2 weeks in patients with localized prostate cancer taking androgen deprivation therapy.
Read More
Guidelines Evolving for the Treatment of Bone Metastases in Castration-Resistant Prostate Cancer
September 30th 2015Androgen deprivation therapy has been the standard of care for patients with advanced prostate cancer (PC), because these agents inhibit cancer progression in the early stages of disease.
Read More
Dr. Sandler Discusses Docetaxel With Hormonal and Radiation Therapy in Patients With Prostate Cancer
September 28th 2015Howard M. Sandler, MD, MS, FASTRO, Cedars Sinai, discusses patient benefit and toxicities of a phase III study of docetaxel with hormonal and radiation therapy of patients with prostate cancer.
Watch
Preventing Bone Metastases Progression in mCRPC: When is it too late?
September 22nd 2015Bone metastases in metastatic castration-resistant prostate cancer (mCRPC) can invade a range of sites in the skeleton where they precipitate a spectrum of pathological processes that increase morbidity, negatively affect quality of life, and decrease survival.
Read More
Dr. Eggener Discusses Racial Disparities in Prostate Cancer
September 15th 2015Scott Eggener, MD, associate professor of surgery, co-director, Prostate Cancer Program, director, Transitional and Outcomes Research, Section of Urology, The University of Chicago Medicine, discusses racial disparities in men with prostate cancer.
Watch
Dr. Loeb Discusses the Controversy of Screening and Treatment in Prostate Cancer
September 10th 2015Stacy Loeb, MD, assistant professor, Urology and Population Health, NYU Langone Medical Center, discusses the controversy of screening and treatment in men with prostate cancer, as well as data from the National Prostate Cancer Register (NPCR) of Sweden.
Watch
Significant OS Benefit Seen With Docetaxel and ADT in Hormone-Sensitive Prostate Cancer
September 9th 2015Administering 6 cycles of docetaxel at the beginning of androgen-deprivation therapy (ADT) to patients with metastatic, hormone-sensitive prostate cancer (mHSPC) resulted in a significantly longer overall survival (OS) than ADT alone.
Read More
Long-term Study Stresses Importance of Active Surveillance in Low-risk Prostate Cancer
September 9th 2015A paper published in the Journal of Clinical Oncology, authored by Tosoian et al, reports on the long-term outcomes of prospective active surveillance (AS) of patients with favorable-risk prostate cancer.
Read More
Multidisciplinary Approach to Radium-223 Treatment Favored for Metastatic Prostate Cancer
September 9th 2015Radium-223 dichloride (Xofigo) has shown a significant survival advantage in the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) who have symptomatic bone metastases, and a multidisciplinary approach to treatment has become more widely practiced in community clinics.
Read More
DIAPH3 Predicts Breast and Prostate Cancer Responses to Chemotherapies
August 18th 2015A publication in Scientific Reports has identified a novel biomarker, diaphanous-related formin-3 (DIAPH3), which may help predict response to taxane-based chemotherapies in patients with metastatic breast or prostate cancer.
Read More
Impact of Immunotherapy on the Treatment of Prostate Cancer
August 6th 2015Matthew Cooperberg, MD, genitourinary cancer specialist, University of California San Francisco, discusses the impact of immunotherapy on the treatment of prostate cancer. Cooperberg believes immunotherapy treatment should be used earlier in the course of the disease.
Watch
Researchers Identify Five Molecular Prostate Cancer Subtypes That Could Change Risk Assessment
August 3rd 2015Treatment decisions in prostate cancer are still largely guided by the classical diagnostic parameters, including Gleason scoring, TNM classification, and prostate specific antigen (PSA) levels, despite growing evidence that molecular signatures may be useful for assessing risk.
Read More